Heart failure (HF) is a common and serious
comorbidity of diabetes. Oxidative stress has
been associated with the pathogenesis of
chronic diabetic complications including cardiomyopathy.
The ability of antioxidants to
inhibit injury has raised the possibility of new
therapeutic treatment for diabetic heart diseases.
Riboflavin constitutes an essential
nutrient for humans and animals and it is an
important food additive. Riboflavin, a precursor
of flavin mononucleotide (FMN) and flavin
adenine dinucleotide (FAD), enhances the
oxidative folding and subsequent secretion of
proteins. The objective of this study was to
investigate the cardioprotective effect of
riboflavin in diabetic rats. Diabetes was
induced in 30 rats by a single injection of
streptozotocin (STZ) (70 mg /kg). Riboflavin
(20 mg/kg) was orally administered to animals
immediately after induction of diabetes and
was continued for eight weeks. Rats were
examined for diabetic cardiomyopathy by left
ventricular (LV) remadynamic function.
Myocardial oxidative stress was assessed by measuring the activity of superoxide dismutase (SOD), the level of malondialdehyde (MDA) as well as heme oxygenase-1 (HO-1) protein level. Myocardial connective tissue growth factor (CTGF) level was measured by Western blot in all rats at the end of the study. In the untreated diabetic rats, left ventricular systolic pressure (LVSP) rate of pressure rose (+dp/dt), and rate of pressure decay (−dp/dt) were depressed while left ventricular enddiastolic pressure (LVEDP) was increased, which indicated the reduced left ventricular contractility and slowing of left ventricular relaxation. The level of SOD decreased, CTGF and HO-1 protein expression and MDA content rose. Riboflavin treatment significantly improved left ventricular systolic and diastolic function in diabetic rats, there were persistent increases in significant activation of SOD and the level of HO-1 protein, and a decrease in the level of CTGF. These results suggest that riboflavin treatment ameliorates myocardial function and improves heart oxidant status, whereas raising myocardial HO-1 and decreasing myocardial CTGF levels have beneficial effects on diabetic cardiomyopathy.
Riboflavin, diabetic cardiomyopathy, heme oxygenase-1.
Guoguang Wang, Department of Pathophysiology, Wannan Medical College, Wuhu 241000, China. E-mail: firstname.lastname@example.org.
Share this Article
Related Content In Heart Failure
Natriuretic Peptide-guided Therapy for Heart Failure
Heart International. 2022;16(2):112–6 DOI: https://doi.org/10.17925/HI.2022.16.2.112
Heart failure (HF) is a complex syndrome caused by a variety of cardiac and non-cardiac diseases, and is associated with high mortality and hospitalization rates.1 Treatment has been traditionally based on a detailed history and physical examination. However, since cardiac biomarkers reflect the pathophysiology of HF, they add information to the clinical findings.1 The most widely used […]
Comparison of Speckle Tracking Echocardiography During Different Pacing Modalities for Cardiac Resynchronization Therapy Response Prediction
Heart International. 2022;16(1):64–70 DOI: https://doi.org/10.17925/HI.2022.16.1.64
Conventionally, according to the European Society of Cardiology pacing and cardiac resynchronization therapy (CRT) guidelines, patients with clinical heart failure and an echocardiographically measured left ventricular (LV) ejection fraction of <35% are considered for CRT implantation or standard right ventricular (RV) pacing (RVP) system upgrade.1 The recommendations for CRT typically follow failure to improve after 3 […]
Management of Atrial Fibrillation in Recipients of Cardiac Resynchronization Therapy
European Journal of Arrhythmia & Electrophysiology. 2021;7(1):19-25 DOI: https://doi.org/10.17925/EJAE.2021.7.1.19
Atrial fibrillation (AF) and heart failure (HF) often co-exist. The incidence of AF is estimated to reach 45% of patients with HF and rises with the severity of HF symptoms, from about 5% of patients in the New York Heart Association (NYHA) class I to 50% in NYHA class IV.1–4 Consistently, the incidence of AF […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!